Imaging Characteristics of a Follow-up 18F-AV-1451 Scan

Stopped early · Phase 2

Conditions studied: Alzheimer's Disease

In brief

This study will evaluate the imaging characteristics of flortaucipir in subjects with a previous flortaucipir scan in order to assess the rate of change of tau deposition over time.

Key facts

Study ID

NCT02051764

Run by

Avid Radiopharmaceuticals

People needed

44

Starts

2014-05-01

Expected to finish

2016-12-01

Last updated by the study team

2020-09-07

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Have a previous 18F-AV-1451 brain scan
• Can tolerate up to two Positron Emission Tomography (PET) imaging sessions and a Magnetic Resonance Imaging (MRI) scan
• Ability to provide informed consent

You may not qualify if…

• Current clinically significant psychiatric disease
• Are claustrophobic
• Current clinically significant cardiovascular disease or ECG abnormalities, or additional risk factors for Torsades de Pointes
• Current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer
• Females of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception
• Have had a non-study related radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session

Where it is running

• Hoag Memorial Hospital — Newport Beach, California, United States
• UC Irvine Medical Center — Orange, California, United States
• Massachusetts General Hospital — Boston, Massachusetts, United States
• Center for Clinical Imaging Research, Washington University School of Medicine — St Louis, Missouri, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.